STUDY OF THE EFFECT OF VALSARTAN ON ADJUVANT-INDUCED ARTHRITIS IN ALBINO RATS

By
Somaia A. Mokbel,

From
department of clinical pharmacolog Mansoura
Faculty of medicine, Egypt.

ABSTRACT

The present work was conducted to investigate the influence of valsartan (a highly selective antagonist on angiotensin II type-1 receptors (AT₁-R blocker) in rats with experimentally - induced inflammation in the form of collagen II- induced adjuvant arthritis.

Thirty two, healthy male albino rats were used throughout this study. Rats were divided into 4 equal groups, each comprised 8 rats. The first group consisted of non-arthritis animals (normal control). This group received intra-gastrically normal saline (the vehicle used to dissolve drugs), for 2 weeks. The second group consisted of arthritic rats that received intra-gastrically saline for 2 weeks & served as an arthritic control. The third group consisted of arthritic rats treated with indomethacin (non-steroidal anti-inflammatory drug, NSAID) in a daily dose of 1.3 mg/kg for the same previously mentioned duration & by the same route of administration. The fourth group consisted of arthritic rats treated with a daily intra-gastric dose of valsartan (20 mg/kg) for 2 weeks.

It was found that administration of collagen II & complete freund's adjuvant to rats produced a significant arthritic changes as assessed by paw oedema thickness, analgesmetric pressure & C-reactive protein (CRP). Furthermore arthritic rats showed a significant increase in fibronectin (fn) & malondialdehyde (MDA) ; an indicator of free oxygen radical. Daily in-
tra-gastric administration of either indomethacin or valsartan induced a significant decrease in the paw oedema thickness, CRP, MDA as well as induced increase in analgesic pressure tolerance, these results suggested that valsartan has a potential anti-inflammatory effect in collagen II induced adjuvant arthritis (this is in addition to its known anti-hypertensive effect).

INTRODUCTION

Angiotensin II (Ang II) has emerged as an important growth factor for vascular, cardiac & renal cells. Depending on the specific cell type & presence of other growth factors, Ang II induces hypertrophy (increase cell size, cell protein & mRNA content without DNA replication), proliferation (replication of DNA with subsequent successful division of cells), apoptosis (programmed cell death) or differentiation. Such Ang II-mediated modulation of growth process may underlie various pathophysiological processes such as atherosclerosis, vascular & cardiac remodeling, and progression of chronic renal disease (1). It is widely accepted that Ang II-1 receptors (AT₁R) account for the majority of cardiovascular effects evoked by Ang II, such as contraction / pressor activity and growth-promoting effects leading to cardiac and vascular hypertrophy. However, there has been increasing evidence indicating that Ang II type-2 receptors (AT₂R) may exert pharmacological action per se as well as play a role in pathophysiological processes. In addition AngII increases expression & production of Fn & collagen type 1, chondroitin / dermatan sulphates & proteoglycans (2). In particular it has been suggested that AT₂R may exert a beneficial vasodilator & anti-growth effects, as well as contribute to the efficacy of AT₁R antagonists(2).

Rheumatoid arthritis (RA) is a common inflammatory autoimmune disorder with a widely varying degree of severity (3). Non-steroidal anti-inflammatory drugs have become an integral part of the rheumatological disorders therapy (4). Patients who are at risk of adverse effects of these drugs are rapidly exposed to well known gastro-intestinal & renal toxicity (5).
Valsartan is a highly a highly selective, orally available antagonist of AT\textsubscript{1} receptors. Valsartan is a non-heterocyclic antagonist in which the imidazole of losartan has been replaced with an acylated amino-acid (see the above figure). Valsartan doesn't need to be metabolized to be effective, and it is excreted both by the bile (70%) & the kidney (30%). There is only one inactive metabolite for Valsartan. Food decreased drug absorption by 40% like losartan, valsartan lacks affinity for adrenergic, histamine, substance P, muscarinic & serotonin receptors (6). It has been suggested that Valsartan had beneficial effects in patients with hypertensive end-organ damage such as renal disease and left ventricular hypertrophy. Furthermore, the drug is evaluated for its efficacy in heart failure and patients with myocardial infarction (7).

Siragy et al., (8) reported that AT1R blockade with Valsartan induced a potential anti-inflammatory effect through prevention of the increase in tumor necrosis factor alpha in diabetic rats. This finding of Valsartan is new in addition to its known anti-hypertensive effects.

MANSOURA MEDICAL JOURNAL
STUDY OF THE EFFECT OF VALSARTAN etc.

Stoboda et al., (9) reported that type II collagen -induced adjuvant arthritis in rats is an experimental model of RA that simulating RA in humans.

The aim of the present work is to study the effect of valsartan in collagen II - induced adjuvant arthritis in rats to declare the above finding in diabetic rats & to study its mechanism. Such possible finding of exerting anti-inflammatory action may be of future benefit to many patients suffering RA in association with cardiovascular diseases (e.g. hypertension) & in need for the use of valsartan to control such problems.

MATERIAL AND METHODS

Drugs used:
- Diovan tab. (Valsartan, 160 mg), supplied by Novartis Co.
- Indocid tab. (indomethacin, 25 mg) supplied by Cairo Co.

Animals used:
Thirty two, healthy, male albino rats aged 3-4 months & weighing 150-200 grams were used throughout the experiment. They were put under similar housing conditions, kept on diet of milk & bread. They, liberally supplied with water.

Animals grouping:
The experiment included 4 equal animal groups, each consisting of 8 rats. They were divided as the following:
- **Group (1)**: non-arthritic control rats treated with intra-gastric saline for 2 weeks (normal control).
- **Group (2)**: arthritic rats treated with intra-gastric saline (the vehicle) & Served as non-treated arthritic control.
- **Group (3)**: arthritic rats treated with indomethacin in a single daily intra-gastric dose of 1.3 mg/kg for 2 weeks (10).
- **Group (4)**: consisted of arthritic rats treated with valsartan in a daily dose of 20 mg/kg/ day by the same previously mentioned route & for the same duration (11).

Adjuvant induced arthritis was produced in albino rats according to Eckhardt (12). Inflammatory & anti-inflammatory effects (pain tolerance & oedema development and suppression) were assessed by using analgesymeter (Fig. 4) & paw oedema tests (Fig. 3) respectively (13,14). CRP was measured by using latex particles agglutination (15). CRP may be the parameter of choice among acute phase proteins that reflects inflamma-
tion (16). Lipid peroxidation was assessed spectrophotometrically by measuring (MDA) using the thiobarbituric acid method (17). Estimation of (Fn) by single radial immuno-diffusion plates. These plates were obtained from Behring werke, AG, Marburg, w. Germany (18). In addition to assessment of serum creatinine according to seeling & wust (19).

STATISTICAL ANALYSIS
Student "t" test according to Pipkins (20), was used to determine the degree of significance between samples. The difference was regarded as significant when P = or < 0.05.

RESULTS
Induction of collagen II – adjuvant arthritis produced a significant decrease in analgesmetric pressure tolerance, significant increase in paw oedema thickness as well as a significant increase in CRP & Fn. (table 1).

Furthermore, arthritic rats showed increase in free oxygen radical as indicated by MDA (Table 2).

Daily administration of either valsartan (20 mg/kg/day) or indomethacin (1.3 mg/kg/day), for 2 weeks produced a significant increase in analgesmetric pressure tolerated by arthritic rats. In addition these rats showed a significant decrease in paw oedema thickness as well as decrease in CRP & MDA, but without changes in serum creatinine. As regards, Fn, there was no significant changes produced by indomethacin. In contrast administration of valsartan to arthritic rats produced significant decrease in Fn. These findings are in comparison to arthritic non-treated control rats: table (1 & 2) & Fig. (1,2,5,6 &7).
STUDY OF THE EFFECT OF VALSARTAN etc..

Table (1): Inflammatory reaction as assessed by analgesmetry, paw oedema thickness, CRP & fn. levels in arthritic & non-arthritic rats (Mean±SE):

<table>
<thead>
<tr>
<th>Group, n=8</th>
<th>Analgesmic pressure (grams)</th>
<th>Paw oedema thickness (mm)</th>
<th>Fibronectin fn. (mg/L)</th>
<th>C-reactive protein CRP. (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Right paw (R)</td>
<td>Left paw (L)</td>
<td>Right paw (R)</td>
<td>Left paw (L)</td>
</tr>
<tr>
<td>Non-arthritic control rats</td>
<td>210±8.1</td>
<td>201±3.3</td>
<td>23±0.12</td>
<td>24.6±0.22</td>
</tr>
<tr>
<td>Arthritic control rats</td>
<td>130±10.5</td>
<td>115±1.3</td>
<td>40.2±0.19</td>
<td>40.8±0.19</td>
</tr>
<tr>
<td>P</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

SE= Standard error.
P = Test of significance between the test group (arthritic rats) & non-arthritic control.

Table (2): Serum Malondialdehyde (MDA) & serum creatinine in arthritic & non-arthritic control rats (mean ±SE):

<table>
<thead>
<tr>
<th>Group n=8</th>
<th>Malondialdehyde (MDA) (mmol/L)</th>
<th>Serum creatinine (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-arthritic control rats</td>
<td>0.12±0.007</td>
<td>0.98±0.02</td>
</tr>
<tr>
<td>Arthritic control rats</td>
<td>0.408±0.02</td>
<td>0.99±0.03</td>
</tr>
<tr>
<td>P</td>
<td>P&lt;0.001</td>
<td>P&gt;0.05 (NS)</td>
</tr>
</tbody>
</table>

SE= Standard error.
NS= non significant
P = Test of significance between non-arthritic & arthritic control group
Fig (1): Effect of either indomethacin or valsartan treatment on analgesmetry (gms).

Fig (2): Effect of either indomethacin or valsartan treatment on paw oedema thickness (cm).

Fig (3): Paw oedema meter.

Fig (4): Analgesymeter.

MANSOURA MEDICAL JOURNAL
Fig (5): Fibronectin immunodiffusion plate of the standard and arthritic control. No 1, 2, 3 = standard, from 4-12, arthritic control.

Fig (6): Fibronectin immunodiffusion plate of arthritic rats treated with indomethacin.

Fig. (7): Fibronectin immunodiffusion plate of arthritic rats treated with valsartan.

Vol. 36, No. 3 & 4 July., & Oct, 2005
DISCUSSION

Inflammatory collagen polyarthritis developed in rats within 45 days after intradermal injection of type II collagen in complete Freund's adjuvant (CFA) as evidenced by a significant decrease in pain threshold & increase in mean hind paw oedema accompanied by increase in serum CRP, fibronectin & free oxygen radical. These results are in accord with that obtained by (21) as they reported that immunization with type II collagen in (CFA) induced polyarthritis & immunity. The immunological mechanisms involved in the pathogenesis of type II collagen induced arthritis was initially suggested by dense polymorphnuclear (PMN) infiltration of synovium of arthritic joint (22 & 23). Stoboda et al., (9) had been reported that type II collagen induced arthritis in rats considered as an experimental model of rheumatoid arthritis occurring in humans. In this model it was speculated that anti-type II collagen antibodies contributed to the incidence of arthritis (24).

Oral administration of indomethacin in a daily dose of 1.3 mg/kg for 2 weeks to rats with adjuvant-induced arthritis produced a significant anti-inflammatory effect as indicated by improvement of paw oedema thickness, pain tolerance, serum CRP & MDA but without a statistically significant changes in serum fibronectin (Fn) or serum creatinine. These findings are in accord with (25). These effects contribute to the analgesic- anti-inflammatory actions of indomethacin. Furthermore it was reported that indomethacin didn't affect renal function (26).

Administration of valsartan in a daily intragastric dose of 20 mg/kg for 2 weeks to rats with adjuvant arthritis produced significant improvement of paw oedema thickness, pain tolerance as well as a significant decrease in elevated serum CRP, MDA & Fn, but without significant changes in serum creatinine as compared to arthritic non-treated rats table (1 & 2). These findings could be explained on the light of previous studies which reported that AngII is responsible for production of $O_2^*$ & $H_2O_2^{**}$ free radicals in cardiac, vascular smooth muscle, endothelial adventitial, and mesangial cells (27, 28, 29). Furthermore, rantes (regulated upon activation, normal T cells expressed and secreted) which is a member of C-C chemokine subfamily with chemoattractant properties for monocytes / macrophages...
(M/M), eosinophils, granulocytes & basophils to T-lymphocytes. Rantes induction is mediated by Ang II. Angiotensin converting enzyme inhibitors (ACEIs) & Ang II-receptor antagonists may be effective in prevention of chemokine induction (30). In addition, it was found that AT1-receptor blockade with valsartan prevented the increase in TNFα in diabetic rats by acting on the Ang II at AT1 receptor levels. TNFα is (M/M) derived cytokine that activates transcription factors such as nuclear factor kappa B (NFkB) which induces expression of genes involved in inflammation & cell growth (31). Fiebeler et al., & Muller et al., (32,33), had been found that valsartan suppressed the nuclear factor KB DNA binding activity & reduced collagen 1 & Fn in the heart. In addition, it was reported that valsartan’s beneficial effect in transgenic rats overexpressing the human renin and angiotensinogen genes (dTGR) are mediated by the inhibition of nuclear factor KB& activator protein-1 (AP-1) (34). Furthermore valsartan protected the kidney from inflammation. This anti-inflammatory effect is not a result of lowering blood pressure, but is a result of direct action on cytokine TNFα at the level of the kidney. This finding made valsartan of potential anti-inflammatory effect(8).

Conclusions:
From this study, it could be concluded that valsartan has comparable anti-inflammatory action as it attenuated the inflammatory response associated with collagen II induced adjuvant arthritis. Clearly, further studies are necessary to declare if this potential anti-inflammatory effect of valsartan occurs in humans.

REFERENCES


32. Fiebeler, A; Schmidt, F; Muller, D.N; Park, J.K; Dechend R, Shagdarssuren E, Bieringer, M; Breu, V; Ganten, D; Luft F.C. & Haller H (2000): Cardiac protective effect of aldosterone blockade is mediated through AP-1 & NF-KB suppression in angiotensin II–induced cardiac damage. Hypertension, 36:691.

33. Muller, D.N; Mervaala, E.M.A; Dechend, R; Fiebeler, A; Park, K.J; Schmidt, F; Thener, J; Breu, V; Mackman, N; Luther, T; Schneider w; Gulba, D; Ganten O, Haller, H. & Luft, F.C. (2000): Angiotensin II (AT1) receptor blockade reduces vascular tissue factor in angiotensin II–induced cardiac vasculopathy. American Journal of Pathology; 157:111-122.

دراسة تأثير دواء الفالسرتان على إلتهاب المفاصل الروماتيزمي المحدث معملياً في الفئران البيضاء

د. سوميه عبد اللطيف مقبل
قسم الفارماكولوجيا الإكلينيكية - كلية الطب
جامعة المنيورة - جمهورية مصر العربية

أجري هذا البحث لدراسة إحتمال وجود تأثير مضاد للالتهاب لدواء الفالسرتان في الفئران البيضاء المصابين بمرض الالتهاب المفصل المحدث معملياً.

استخدام لإجراء هذا البحث عدد 32 فأراً أليباً تقسم إلى أربعة مجموعات متساوية كل مجموعة تكون من 8 فئران كالآتي:

المجموعة الأولى: مجموعة ضبطة عادية - لم يحدث بها التهاب مفصلي روماتيزمي، أعطيت محلول ملح عادي بنفس الكمية المستخدمة لإدراك الدواء وذلك لمدة أسبوعين متتاليين.

المجموعة الثانية: عبارة عن فئران مصابة بالتهاب المفاصل أعطيت أيضاً محلول الملح عن طريق الفم (مجموعة ضبطة للالتهاب)، وذلك بنفس الجرعة ولنفس المدة.

المجموعة الثالثة : أحدث بها مصابة التهاب مفصلي وعولت بدءاً بالاندروميتشين بجرعة 1.5 مجم/كجم يومياً وذلك عن طريق الفم لمدة أسبوعين متتاليين أيضاً.

المجموعة الرابعة : أحدث بها مصابة التهاب مفصلي وعولت بدءاً الفالسرتان بجرعة 20 مجم/كجم يومياً وذلك عن طريق الفم لمدة أسبوعين متتاليين أيضاً.

وتم تقييم الإلتهاب المفصلي الروماتيزمي بواسطة المعايير الآتية:

- قياس حجم الورم في المخلب الخلفي للفئران بواسطة جهاز الاديميتر.
- قياس مدى تحمل الألم بإحداث ضغط على المخلب الخلفي بواسطة جهاز الأنجلينر ميتر.
- قياس مستوى البروتين - ج المتفاعل في المصل.

MANSOURA MEDICAL JOURNAL
قياس معدل الشفقات الحرة في المصل.
قياس معدل الفيبرونكتين في المصل.
قياس معدل الكرياتينين في المصل.

وكانت نتائج هذا البحث كالتالي:

- حدث الالتهاب المفصلي نقش ذو دلالة إحصائية في مدى تحمل الألم بإحداث ضغط على المخلب الخلفي.

- حدث الالتهاب المفصلي زيادة ذات دلالة إحصائية في حجم الورم في المخلب الخلفي للفنان.

- حدث الالتهاب المفصلي زيادة ذات دلالة إحصائية في مستوي البروتين - ج المناعي في المصل وكذلك في معدل الشفقات الحرة في المصل وعند الفيبرونكتين في المصل مع عدم تغيير في معدل الكرياتينين في المصل.

- إعطاء دواء الاندوميسياتين للفنان كان يؤدي لثقافة المصل بالражمات المناعية بالجرعات السابقة ذكرها أحدها زيادة ذات دلالة إحصائية في مدى تحمل الألم. وكذلك أحدها نقش ذو دلالة إحصائية في حجم الورم في المخلب الخلفي وأيضاً أحدث نقش ذو دلالة إحصائية في كل من مستوي البروتين - ج وفي معدل الشفقات الحرة في المصل بينما ظل معدل الفيبرونكتين في المصل دون تغيير وكذلك معدل الكرياتينين في المصل.

- وذلك بالمقارنة بالجودة المضافة المصلية بالتهاب المفصل.

على ضوء هذه الدراسات يمكن استخلاص أن دواء الفالسرتين له تأثير مشترك في الحالة المفصلية الروماتيزمية في الفنان العامل، وصحة المصلية ويحسن الإسهال مع ذلك بالمقارنة بدواء الأنثوسياتين المنشط للالتهاب المفصلي.

وبينما على ذلك نوصي بدراستها هذا التأثير في مرضى الالتهاب الروماتيزمي وخصوصاً المرضى منهم الصيانة في نفس الوقت بإرتفاع ضغط الدم الشرياني وفي حاجة إلى علاج وذلك لتقليل الأعراض الجانبية وتبديل نتائج المراقبة.

Vol. 36, No. 3 & 4 July., & Oct, 2005